Trump Appoints Michael Caputo to President's Cancer Panel

What the President's Cancer Panel Does — and Why Caputo Was Named to It

The U.S. Department of Health and Human Services announced on October 4, 2026, that Michael R. Caputo has been appointed to the President's Cancer Panel. The panel is an independent federal advisory body created by the National Cancer Act of 1971. Its job is to monitor how the National Cancer Program is developed and executed, and to report to the President on progress, effectiveness, and opportunities for improvement in the national fight against cancer.

Caputo brings 35 years of experience in global public affairs across government, public policy, political campaigns, and the private sector. He served as Assistant Secretary for Public Affairs at HHS in 2020, where he led the department's communications during the COVID-19 response and helped establish and guide Operation Warp Speed. He is also co-founder and Executive Vice President of Ave Maria Biotech, which makes an indoor airborne virus detector, and he advises the global law firm Boies Schiller Flexner on international public affairs strategy and City of Hope Cancer Institute on work related to the Trump Administration's Make America Healthy Again policy initiative.

In statements released with the announcement, HHS Secretary Robert F. Kennedy, Jr. said Caputo "understands how to bring people together, challenge conventional thinking, and turn ambitious goals into action" and will help drive a national cancer strategy focused on prevention, innovation, transparency, and results. Caputo said cancer is personal to him because he faced the disease himself and overcame it, adding that he knows what a diagnosis means for patients and families. Anthony Letai, M.D., Ph.D., director of the National Cancer Institute, said the panel identifies important issues and delivers actionable recommendations directly to the President that are passed down to the NCI and the broader cancer community, and that Caputo's experience as a survivor will help keep patients and families at the center of that work.

Caputo's Biotech and Policy Ties Meet a Panel Built for Recommendations

Why the Panel's Reporting Line Matters

The President's Cancer Panel is not a research agency or a grant-making body. Its leverage comes from its direct reporting relationship to the President and its mandate to assess the National Cancer Program's progress and shortcomings. Recommendations that reach the President can then flow to the National Cancer Institute and the wider cancer community, as NCI Director Anthony Letai described in the announcement. That makes the panel's membership a signal of which priorities and perspectives are likely to be elevated in national cancer strategy discussions.

Caputo's Profile: Communications, Biotech, and Policy Networks

Caputo's background is unusual for a cancer advisory panel. His career has centered on public affairs, political campaigns, and government communications rather than oncology research or clinical practice. At HHS in 2020 he led communications during the COVID-19 response and helped establish Operation Warp Speed — experience that ties him to a high-profile federal health initiative and to the operational side of accelerating medical countermeasures. He also co-founded Ave Maria Biotech, which makes an indoor airborne virus detector, and advises City of Hope Cancer Institute on work related to the Make America Healthy Again initiative. Those roles suggest he brings both a private-sector biotech perspective and existing relationships with cancer-focused institutions.

Prevention, Innovation, and Transparency as Stated Priorities

Secretary Kennedy's statement framed the appointment around a national cancer strategy prioritizing prevention, innovation, transparency, and results. Caputo's own statement emphasized prevention, accelerating innovation, and helping more Americans overcome cancer. For context, the panel's statutory role is to monitor and report, so its influence depends on how its recommendations are received by the President, NCI, and the broader cancer community. The appointment does not itself change the National Cancer Program's funding or operations, but it places a communications and policy operator in a position to help shape how the panel frames its findings.

What to Watch in the Panel's Work

The practical effect of any panel appointment shows up in the issues it chooses to highlight and the recommendations it forwards. Caputo's survivor experience and his stated focus on patients and families may influence how the panel addresses prevention and patient-centered concerns. His biotech and advisory ties could also shape how the panel engages with innovation and private-sector perspectives. Because the panel reports to the President and its recommendations are passed to NCI and the cancer community, the next visible signal will be the panel's future reports and the specific opportunities or gaps it chooses to flag.

What This Appointment Means for Cancer Stakeholders

The appointment puts a communications and policy operator with biotech ties into a body whose main output is recommendations to the President on the National Cancer Program.

• Cancer-focused organizations and research institutions should note Caputo's stated priorities — prevention, innovation, transparency, and results — as likely themes in the panel's future reports and recommendations.
• Biotech and diagnostics companies, particularly those working on prevention or detection, may find the panel's innovation focus relevant to how national cancer priorities are framed.
• Patient advocacy groups can watch for how Caputo's survivor experience shapes the panel's attention to patient and family concerns.
• Track the panel's next reports and any recommendations passed to the National Cancer Institute, since those are the concrete outputs of its mandate.